Targeted Therapeutic Mild Hypercapnia After Resuscitated Cardiac Arrest: A Phase III Multi-Centre Randomised Controlled Trial (The TAME Cardiac Arrest Trial)
Funder
National Health and Medical Research Council
Funding Amount
$2,069,878.00
Summary
The TAME Cardiac Arrest trial will study the ability of higher carbon dioxide (CO2) levels to reduce brain damage, comparing giving patients ‘normal’ to ‘slightly higher than normal’ blood CO2 levels and assessing their ability to return to normal life-tasks. It will be the largest trial ever conducted in heart attack patients in the ICU. This therapy is cost free and, if shown to be effective, will improve thousands of Australian lives, transform clinical practice, and yield major savings.
Reduction Of Oxygen After Cardiac Arrest: The EXACT Trial
Funder
National Health and Medical Research Council
Funding Amount
$1,891,021.00
Summary
We aim to conduct a Phase 3 multi-centre, randomised, controlled trial to determine whether reducing oxygen administration to target a normal level as soon as possible following successful resuscitation from out-of-hospital cardiac arrest, compared to current practice of maintaining 100% oxygen, improves patient survival at hospital discharge.
The Impact Of Introducing Medical Emergency Team On The Reduction Of Hospital Mortality And Other Adverse Events In NSW
Funder
National Health and Medical Research Council
Funding Amount
$581,827.00
Summary
High numbers of patients suffer an adverse event or die in hospitals needlessly. Summoned by a set of pre-specified criteria, a Medical Emergency Team (MET) rapidly respond to patients on general wards to prevent further deterioration. Previous studies have shown its impact on reducing cardiac arrests but limited high level evidence on reducing hospital deaths. Current study uses linked administrative databases and well-established indicators to assess the impact of introduction of a MET in NSW.
The Evaluation Of A Statewide Innovative Patient Safety Improvement System On Reducing Hospital Mortality And Other Adverse Events - A Population-based Mixed-method Study
Funder
National Health and Medical Research Council
Funding Amount
$724,555.00
Summary
Research indicates that one in ten patients admitted to hospital suffered an adverse event. Studies have shown that the adverse clinical outcomes (e.g. cardiac arrest or death) often exhibit early warning signs such as slow deterioration of vital signs hours before such an event. Clinical Excellence Commission of NSW implemented a world-first standardised patient safety system (i.e., Between the Flag) to address the issues. We aim to provide an evaluation of the effectiveness of this system.
The RINSE Trial: The Rapid Infusion Of Cold Normal SalinE By Paramedics During CPR
Funder
National Health and Medical Research Council
Funding Amount
$708,241.00
Summary
Sudden cardiac arrest is a common event in the community. Therapeutic hypothermia decreases the brain injury caused by the cardiac arrest and is currently used in the hospital after successful resuscitation. However, there may be better outcomes if the brain is cooled by paramedics during resuscitation. We will compare survival rates for those patients cooled early by paramedics using an infusion of ice-saline during cardiac arrest with those patients who are later cooled by the hospital.
Clinical, Genetic And Psychosocial Aspects Of Sudden Cardiac Death
Funder
National Health and Medical Research Council
Funding Amount
$433,423.00
Summary
Sudden cardiac death (SCD) in the young is a tragic complication of a number of genetic heart diseases. Families must deal with profound grief and act on the genetic risk to themselves and other relatives. Clinical management can include the implantable cardioverter defibrillator (ICD) and is the only therapy proven to prevent SCD. This proposal seeks to investigate the clinical, genetic and psychosocial aspects of managing families who present following a SCD, including psychological outcomes o ....Sudden cardiac death (SCD) in the young is a tragic complication of a number of genetic heart diseases. Families must deal with profound grief and act on the genetic risk to themselves and other relatives. Clinical management can include the implantable cardioverter defibrillator (ICD) and is the only therapy proven to prevent SCD. This proposal seeks to investigate the clinical, genetic and psychosocial aspects of managing families who present following a SCD, including psychological outcomes of life-saving ICD therapy.Read moreRead less